BR9807627A - Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos. - Google Patents

Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos.

Info

Publication number
BR9807627A
BR9807627A BR9807627-2A BR9807627A BR9807627A BR 9807627 A BR9807627 A BR 9807627A BR 9807627 A BR9807627 A BR 9807627A BR 9807627 A BR9807627 A BR 9807627A
Authority
BR
Brazil
Prior art keywords
factor
analogue
preparation containing
preparation
preparing
Prior art date
Application number
BR9807627-2A
Other languages
English (en)
Inventor
Michele Himmelspach
Uwe Schlokat
Friedrich Dorner
Andreas Fischer
Johann Eibl
Original Assignee
Baxter Aktiengesellchaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Aktiengesellchaft filed Critical Baxter Aktiengesellchaft
Publication of BR9807627A publication Critical patent/BR9807627A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANáLOGO DE FATOR X, DNA RECOMBINANTE CODIFICANTE PARA UM ANáLOGO DE FATOR X, PREPARAçãO CONTENDO UM ANáLOGO DE FATOR X PURIFICADO OU UMA SUA PROTEìNA PRECURSORA, PREPARAçãO CONTENDO ANáLOGO DE FATOR XA APRESENTANDO ALTA ESTABILIDDE E INTEGRIDADE ESTRUTURAL, USOS DE UMA PREPARAçãO E DE UM áCIDO NUCLEICO, E, PROCESSOS PARA A PREPARAçãO DE UM PREPARADO CONTENDO ANáLOGO DE FATOR X RECOMBINANTE PURIFICADO, E PARA SE PREPARAR UM PREPARADO CONTENDO FATOR XA OU ANáLOGO DE FATOR XA ATIVOS". A invenção refere-se a análogos de Fator X que têm uma modificação na área do sítio de clivagem de ativação de Fator Xa naturalmente ocorrente, sendo que a referida modificação representa um sítio de processamento de uma protease que não cliva naturalmente nesta área da seq³ência do Fator X. A invenção também refere-se a preparações contendo os inéditos análogos de Fator X e a processos para sua produção.
BR9807627-2A 1997-02-27 1998-02-27 Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos. BR9807627A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0033597A AT405516B (de) 1997-02-27 1997-02-27 Faktor x-analoge mit modifizierter proteasespaltstelle
PCT/AT1998/000045 WO1998038317A1 (de) 1997-02-27 1998-02-27 Faktor x-analoge mit modifizierter proteasespaltstelle

Publications (1)

Publication Number Publication Date
BR9807627A true BR9807627A (pt) 2000-02-22

Family

ID=3487868

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807627-2A BR9807627A (pt) 1997-02-27 1998-02-27 Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos.

Country Status (17)

Country Link
US (2) US6573071B1 (pt)
EP (1) EP0966536B1 (pt)
JP (1) JP4317976B2 (pt)
AR (1) AR012034A1 (pt)
AT (2) AT405516B (pt)
AU (1) AU744428B2 (pt)
BR (1) BR9807627A (pt)
CA (1) CA2282707A1 (pt)
CZ (1) CZ298298B6 (pt)
DE (1) DE59813518D1 (pt)
ES (1) ES2263199T3 (pt)
HU (1) HU225246B1 (pt)
IL (2) IL131346A0 (pt)
NO (1) NO327878B1 (pt)
PL (1) PL190734B1 (pt)
SK (1) SK286359B6 (pt)
WO (1) WO1998038317A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
IL129427A0 (en) 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
US7223577B2 (en) * 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
US20040132156A1 (en) * 2002-10-04 2004-07-08 Schering Aktiengesellschaft Modified hepsin molecules having a substitute activation sequence and uses thereof
BRPI0514396A2 (pt) * 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
EP1728798A1 (en) * 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
CA2649800C (en) 2006-04-20 2016-09-20 Kringle Pharma Inc. Hgf precursor protein variant and active protein thereof
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
CN101802188B (zh) 2007-09-28 2013-08-21 普托拉制药有限公司 用于因子Xa抑制剂的解毒剂和其使用方法
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
US20120263701A1 (en) * 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
LT2814840T (lt) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2013130683A2 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten conjugate compositions and methods of making same
GB201211617D0 (en) 2012-06-29 2012-08-15 Univ Aberdeen Production of cyclic peptides
US9145552B2 (en) 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof
MX2015008813A (es) 2013-01-31 2016-03-31 Pfizer Composiciones y metodos para contrarrestar la inhibicion del factor xa.
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
US20160024487A1 (en) * 2013-03-12 2016-01-28 Novo Nordisk A/S Thrombin sensitive coagulation factor x molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
MX2016003871A (es) 2013-09-24 2016-08-04 Pfizer Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.
RU2585532C2 (ru) * 2014-01-31 2016-05-27 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук"(ФИЦ Биотехнологии РАН) Плазмида для экспрессии рекомбинантного фактора свёртываемости крови ix человека, клетка сно - продуцент рекомбинантного фактора свёртываемости крови ix человека и способ получения указанного фактора
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
EP4129327A1 (en) 2015-08-28 2023-02-08 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
KR102613936B1 (ko) * 2020-11-13 2023-12-15 한국생명공학연구원 자가분해능이 저하된 켁신 효소 및 이의 생산 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT366916B (de) * 1980-04-02 1982-05-25 Immuno Ag Vorrichtung zur applikation eines gewebeklebstoffes auf basis von menschlichen oder tierischenproteinen
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
AT382783B (de) * 1985-06-20 1987-04-10 Immuno Ag Vorrichtung zur applikation eines gewebeklebstoffes
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DE4325872C1 (de) 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon

Also Published As

Publication number Publication date
NO327878B1 (no) 2009-10-12
NO994139L (no) 1999-10-27
HUP0100652A3 (en) 2003-01-28
AT405516B (de) 1999-09-27
WO1998038317A1 (de) 1998-09-03
PL335382A1 (en) 2000-04-25
US7220569B2 (en) 2007-05-22
US20030181381A1 (en) 2003-09-25
IL131346A0 (en) 2001-01-28
AU744428B2 (en) 2002-02-21
SK286359B6 (sk) 2008-08-05
AR012034A1 (es) 2000-09-27
NO994139D0 (no) 1999-08-26
AU6200298A (en) 1998-09-18
ES2263199T3 (es) 2006-12-01
JP2001513631A (ja) 2001-09-04
SK117199A3 (en) 2000-05-16
CZ303299A3 (cs) 2000-02-16
IL131346A (en) 2007-05-15
JP4317976B2 (ja) 2009-08-19
HUP0100652A1 (hu) 2001-06-28
ATE324454T1 (de) 2006-05-15
EP0966536B1 (de) 2006-04-26
PL190734B1 (pl) 2005-12-30
HU225246B1 (en) 2006-08-28
DE59813518D1 (de) 2006-06-01
CA2282707A1 (en) 1998-09-03
ATA33597A (de) 1999-01-15
CZ298298B6 (cs) 2007-08-22
EP0966536A1 (de) 1999-12-29
US6573071B1 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
BR9807627A (pt) Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos.
Nutt et al. The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure.
RU95115239A (ru) Аналог эритропоэтина
HUP9902698A2 (hu) Humán bikunin
Grant et al. Biosynthesis of an insulin precursor by islet tissue of cod (Gadus callarias)
AU4880093A (en) Retrovirus from the HIV group and its use
DK471085D0 (da) Farmaceutiske sammensaetninger indeholdende syntetiske phospholipiderog et farmaceutisk aktivt stof samt deres fremstilling og anvendelse
ATE68014T1 (de) Die synthese eines proteins mittels eines identifizierungspeptids.
PT81168B (pt) Processo para a preparacao de proteinas inibidoras da coagulacao do sangue e de composicoes farmaceuticas contendo estas substancias
HUP9800075A2 (hu) Nukleinsav-konstrukciók proteázokkal aktíválható hatóanyagok expresszálására valamint előállításuk és alkalmazásuk
ATE84048T1 (de) Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung.
PT93082A (pt) Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado
ATE63823T1 (de) Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha.
PT81991B (pt) Processo para a preparacao de derivados peptidicos, analogos a pepestatina, inibidores darenina e das proteases acidas
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
BR9710615A (pt) Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea.
US5397694A (en) Protease inhibitor
Tam et al. The importance of disulfide bridges in human endopeptidase (enkephalinase) after proteolytic cleavage
PT83045B (pt) Processo para a obtencao de derivados aminoalcoois peptidicos contendo um atomo de carbono tetrasubstituido inibidores da renina e das proteases acidas
EP0210279A4 (en) STABILIZED HUMAN PROUROKINASE.
PT81345B (pt) Processo para a preparacao de novos peptideos activos sobre o sistema nervoso central com accao sobre o sistema colinergico, e de composicoes farmaceuticas contendo estes compostos
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
PT704527E (pt) Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina
PT83939B (pt) Metodo para a producao de factor angiogenico da placenta humana capaz de estimular a sintese de proteases, sintese de dna e migracao de celulas endoteliais capilares

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A, 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1887 DE 06/03/2007.